SES
The Luxembourg Directorate of Defence (DoD) procured two ground stations following a competitive call for tender to enable the Luxembourg Army to improve its resilience by accessing secure satellite communications services, the DoD, SES and HITEC Luxembourg said today.
The ground stations, which will be installed at the Luxembourg Army’s Military Centre in Diekirch, will be used for Luxembourg’s GovSat-1 satellite services in X- and Military Ka-band frequencies, as well as for the Wideband Global Satcom (WGS) system, the backbone of the satellite communications capability of the U.S. DoD.
The addition of the two new ground stations reinforce resiliency and augment the existing Luxembourg Army satcom infrastructure already built by SES and HITEC Luxembourg 10 years ago, bringing the total number of dedicated antennas to four. The new ground stations unlock the strong potential to scale and add interoperability with the NATO partner systems, in line with the country’s defence strategy for the years to come.
Yuriko Backes, Luxembourg Minister of Defence: “Access to secure satellite communications has always been among the priorities and strengths of Luxembourg, allowing the country to reinforce defence capabilities, as well as enabling fulfillment of Luxembourg’s commitments towards the EU and NATO. To keep the upper technological edge, we will continue to leverage Luxembourg’s globally-renowned expertise in the space sector, to increase our resilience, including that of our armed forces.”
“It is an honour for SES to help strengthen the Luxembourg Government’s defence pillar by adding resiliency to its secure satcom,” said Adel Al-Saleh, CEO of SES. “Following the successful implementation of the initial ground stations by the Luxembourg Army, we are delighted to extend its communications infrastructure that leverages Luxembourg’s GovSat-1 and enhances interoperability with the partner systems.”
“We are proud to be part of the project and once again join efforts with SES to help augment Luxembourg’s defence capabilities with resilient and proven technology,” said Philippe Osch, CEO of HITEC Luxembourg. “The ground terminals to be supplied for the Luxembourg Army’s satcom infrastructure are a source of particular pride for us as they combine the latest technological innovations and a track-record of superior “Made in Luxembourg” quality.”
Follow us on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a leader in global content connectivity solutions, SES owns and operates the world’s only geosynchronous orbit and medium earth orbit (GEO-MEO) constellation of satellites with the unique combination of global coverage and high performance. By leveraging its vast and intelligent, cloud-enabled network, SES delivers high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 6,400 channels, reaching 369 million households, delivering managed media services for both linear and non-linear content. The company is headquartered in Luxembourg and listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com
About HITEC Luxembourg
HITEC Luxembourg S.A., a 100%-owned Luxembourg company, has developed its business activities in the field of innovative and quality products and services.
HITEC offers high technology solutions covering different business areas: satellite ground segment; specific and standard equipment for testing and measuring of physical properties; traffic management; mission critical; engineering; consulting; software & ICT development and project management. HITEC serves private and public sector customers at a national and international level.
In our daily commitment, know-how, creativity, quality and perseverance are an integral part of HITECs’ undertaking. Enthusiasm for technology and innovation and a dedication to life-long-learning are core elements of our company culture, reflected by our highly qualified and motivated staff.
HITEC is ISO 9001, ISO 14001, ISO 45001 and AQAP 2110 certified and has several labels, such as “SuperDrecksKëscht fir Betriber“ (ISO 14024:2000 Standard), “Entreprise Socialement Responsable”, delivered by the indr, Responsibility Europe, Made in Luxembourg (for most of the products & services) and is signatory of the IMS Diversity Charter and the “Pacte National – Entreprises et Droits de l’Homme Luxembourg”. HITECs’ motto: market-oriented, client-centric and technology driven.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222299678/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom